Quantcast
Last updated on April 24, 2014 at 13:44 EDT

Latest Parkinson's Stories

2013-07-12 16:22:16

PHOENIX, July 12, 2013 /PRNewswire/ -- First experiencing symptoms at just 29-years-old and diagnosed with Parkinson's at age 34, Tommy Zuleger is the youngest patient ever treated at the Muhammad Ali Parkinson Center at Barrow Neurological Institute in Phoenix and he says a new "sci-fi" procedure has given him his life back. (Photo: http://photos.prnewswire.com/prnh/20130712/LA46804) The real estate executive recently underwent a new procedure at Barrow called Asleep Deep Brain...

2013-06-27 16:25:05

NEW YORK, June 27, 2013 /PRNewswire-USNewswire/ -- The Parkinson's Disease Foundation® (PDF®) is pleased to announce $1 million in funding for 14 global research projects designed to improve the lives and futures of people touched by Parkinson's disease. For summaries of each one, visit www.pdf.org/en/parkinson_research_grantees. (Logo: http://photos.prnewswire.com/prnh/20111101/DC97663LOGO) "There are one million people like me living with Parkinson's disease, who urgently...

2013-06-04 16:24:32

NEW YORK, June 4, 2013 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation for Parkinson's Research (MJFF) has committed up to $10 million to its next funding round for the Edmond J. Safra Core Programs for PD Research to prioritize research toward transformative treatments and a cure for Parkinson's disease (PD). The Edmond J. Safra Core Programs include the Rapid Response Innovation Awards, focused on breakthrough ideas, Target Validation, which supports testing of biological targets...

2013-06-03 08:26:49

NESS ZIONA, Israel, June 3, 2013 /PRNewswire/ -- NeuroDerm, Ltd. was informed today that it was awarded, for the second time, a grant of $1M by The Michael J. Fox Foundation for Parkinson's Research (MJFF) to support the clinical development of its subcutaneously delivered drug for the treatment of Parkinson's disease. These funds, part of the Foundation's 2013 Therapeutic Pipeline program, will support an upcoming phase 2 clinical trial with ND0612, a novel drug for the...

2013-05-31 16:23:41

NEW YORK, May 31, 2013 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation for Parkinson's Research (MJFF) announced that Alim Louis Benabid, MD, PhD, is the recipient of the 2013 Robert A. Pritzker Prize for Leadership in Parkinson's Research. The prize recognizes an honoree's contribution to Parkinson's research as well as an exceptional commitment to mentoring the next generation of Parkinson's scientists. Professor Benabid, widely recognized as the inventor and pioneer of...

2013-05-21 08:30:12

More than 10,000 Walkers Make Every Step Count in Raising Funds and Awareness for Parkinson's KINGSTON, N.J., May 21, 2013 /PRNewswire-USNewswire/ -- The Parkinson Alliance proudly announced today that the 19th Parkinson's Unity Walk held on Saturday, April 27, 2013 in New York City's Central Park, has thus far raised more than $1.6 million and united more than 10,000 walkers in raising awareness for Parkinson's disease and to support research for better treatments, and hopefully...

2013-05-21 08:28:22

Clinical Data on CERE-120 (AAV-NRTN) Presented at the 16th Annual Meeting of the American Society of Gene and Cellular Therapy (ASGCT) SAN DIEGO, May 21, 2013 /PRNewswire/ -- Ceregene, Inc. today announced additional efficacy data from a secondary analysis of its double-blind, randomized, controlled Phase 2b clinical study of CERE-120 (AAV-neurturin). CERE-120 is a gene therapy product designed to deliver the neurotrophic factor neurturin, for Parkinson's disease. This exploratory...

2013-05-06 08:26:20

CARDIFF, Calif., May 6, 2013 /PRNewswire/ -- NI Research, the leading publisher of independent research on the neurotherapeutics industry, has released the May issue of NeuroPerspective, which reviews the status and prospects of therapeutics for Parkinson's. "The current therapeutic options for PD are limited in scope and duration of utility. Motoric symptoms can be attenuated, but over time, there is a price to be paid, as L-dopa related dyskinesias eventually emerge for many patients,"...

2013-04-24 12:30:17

NEW YORK, April 24, 2013 /PRNewswire-USNewswire/ -- Researchers from LIONsolver, Inc. have won first prize in The Michael J. Fox Foundation's $10,000 Parkinson's Data Challenge, a contest leveraging "the wisdom of the crowd" to benefit people with Parkinson's disease (PD). The contest received an enthusiastic response from the scientific community -- the winning entry was chosen following more than 630 downloads of the dataset from teams in 21 countries. The LIONsolver team's winning entry...

2013-04-23 12:33:14

--Study completes enrollment of original 600-member cohort; infrastructure and open-source model are transforming biomarker research-- NEW YORK, April 23, 2013 /PRNewswire-USNewswire/ -- The Parkinson's Progression Markers Initiative (PPMI), a landmark biomarker clinical study, has completed enrollment of its initial 600-member cohort of Parkinson's patients and controls, and will launch additional study cohorts to leverage the existing PPMI infrastructure and evaluate multiple...